Drug updated on 4/16/2024
Dosage Form | Injection (intravenous: 500 mg (1,000 mg/m2 over 30 minutes)) |
Drug Class | Histone deacetylase inhibitors |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Summary
- Belinostat (Beleodaq) is indicated for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) and has shown promising results, particularly as part of combination therapies.
- Two studies were reviewed to gather information about Beleodaq, providing insights into its efficacy and safety profile compared to other drugs.
- In terms of efficacy, belinostat showed a complete response rate of 14% in relapsed or refractory PTCL cases, slightly lower than romidepsin, which had a response rate of 17%, but higher than chidamide at 10%.
- The drug demonstrated increased effectiveness within certain subgroups; specifically, it achieved an overall response rate (ORR) as high as 44% among patients with angioimmunoblastic T-cell lymphoma, a subtype of PTCL.
- Common adverse events associated with belinostat include thrombocytopenia and nausea. However, these side effects are considered manageable and do not significantly distinguish Beleodaq unfavorably from alternative treatments in terms of safety profile.
- When treating cutaneous T-cell lymphomas (CTCL), alternatives such as brentuximab vedotin and bexarotene may be more effective, given their ORRs exceeding 50%. As such, while Beleodaq remains valuable for treating PTCL, especially in relapsed or refractory settings, there might be safer and more effective options available depending on individual patient conditions.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Beleodaq (belinostat) prescribing information. | 2023 | Acrotech Biopharma LLC, East Windsor, NJ |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Efficacy and safety of histone deacetylase inhibitors in peripheral T-cell lymphoma: A systematic review and meta-analysis on prospective clinical trials. | 2023 | Frontiers in Oncology |
The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: Results of a systematic review. | 2020 | Expert Review of Hematology |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
T-cell lymphomas, version 2.2022, NCCN clinical practice guidelines in oncology. | 2022 | Journal of the National Comprehensive Cancer Network |